Overview

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.
Phase:
Phase 3
Details
Lead Sponsor:
Akeso